Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
In this adaption of our platform technology, we leverage proprietary genetic engineering interventions to build on the natural ability of our bacterial strains to seek out and colonise solid tumours. We have developed attenuated strains capable of targeting tumours without causing pathology in normal tissues. These strains are also capable of delivering specific immunostimulatory cargo aimed at activating the patient’s immune system to destroy tumours.
NMIBC Therapeutic
Bladder cancer represents 5% of all new cancer cases in the US and accounts for 550,000 new cases yearly worldwide. The clinical staging is determined by the depth of invasion into the bladder wall and more than 70% of cases are diagnosed at an early-stage, also known as Non Muscle Invasive Bladder Cancer (NMIBC). Despite the early diagnosis, the only approved therapies are Bacillus Calmette–Guérin (BCG), which often faces shortages, and chemotherapy, both delivered intravescically. Because of its high incidence and the low number of treatment options, a huge unmet medical need remains in NMIBC.
Undisclosed
Prokarium is investigating the use of engineered bacteria as immunotherapy to treat solid tumours. Onconella has the ability to sense and kill tumour cells and, in addition, to boost the natural anti-tumoral activity of the immune system.
S. Typhi and S. Paratyphi A Vaccine
FIH Phase 1 Readout
1H2021
Enteric fever, a preventable illness caused by Salmonella enterica serovars Typhi and Paratyphi A, is the most common bacterial bloodstream infection in South Asia. It has been estimated to cause >15 million illnesses and nearly 153,000 deaths worldwide annually.
Entervax™, a novel, oral bivalent vaccine against enteric fever, is based on the Vaxonella® platform and is the combination of our proprietary strain ZH9 (Salmonella enterica serovar Typhi ZH9), plus a novel strain modified to express antigens specific to S. Paratyphi A.
NMIBC Therapeutic
Bladder cancer represents 5% of all new cancer cases in the US and accounts for 550,000 new cases yearly worldwide. The clinical staging is determined by the depth of invasion into the bladder wall and more than 70% of cases are diagnosed at an early-stage, also known as Non Muscle Invasive Bladder Cancer (NMIBC). Despite the early diagnosis, the only approved therapies are Bacillus Calmette–Guérin (BCG), which often faces shortages, and chemotherapy, both delivered intravescically. Because of its high incidence and the low number of treatment options, a huge unmet medical need remains in NMIBC.
Undisclosed
Prokarium is investigating the use of engineered bacteria as immunotherapy to treat solid tumours. Onconella has the ability to sense and kill tumour cells and, in addition, to boost the natural anti-tumoral activity of the immune system.
S. Typhi and S. Paratyphi A Vaccine
FIH Phase 1
1Q2020
Enteric fever, a preventable illness caused by Salmonella enterica serovars Typhi and Paratyphi A, is the most common bacterial bloodstream infection in South Asia. It has been estimated to cause >15 million illnesses and nearly 153,000 deaths worldwide annually.
Entervax™, a novel, oral bivalent vaccine against enteric fever, is based on the Vaxonella® platform and is the combination of our proprietary strain ZH9 (Salmonella enterica serovar Typhi ZH9), plus a novel strain modified to express antigens specific to S. Paratyphi A.
Situated within one of the largest hubs of life science and biotechnology companies in the UK, Prokarium offers a multitude of career opportunities within the microbial immunotherapy space. We are working hard to bring novel therapies for bladder cancer and other solid tumours into the clinic to improve cancer patients’ lives.
Join our team to unlock the next level of immuno-oncology!
Prokarium 2022 © All Rights Reserved.
CEO
CEO
Kristen joined Prokarium in 2018, most recently serving as Chief Operating Officer, and has led Prokarium’s expanding development efforts in oncology while also securing an investment from The Wellcome Trust to fund the company’s lead vaccine program into clinical development. Prior to Prokarium, Kristen was an investor at Osage University Partners, where she led several investments into life sciences companies. Earlier in her career, she worked within business development at Emergent BioSolutions and Cangene Corporation, where she specialized in asset licensing and mergers and acquisitions. She started her industry career as a Post-Doctoral Fellow at Centocor. Kristen holds an MBA from Saint Joseph’s University and earned her Doctor of Pharmacy from the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia.
CSO
CSO
Livija joined Prokarium in 2018 as the VP Immunology and Oncology. She is leading the strategic and operational development of Prokarium’s immuno-oncology portfolio. As an immunologist Livija specializes in mucosal and tumour immunology, immunological assay development and immuno-oncology. Prior to joining Prokarium, Livija headed the lead selection and immuno-oncology R&D at Oxford BioTherapeutics where she focused on the target discovery and the development of immunomodulatory antibodies for cancer treatment. She has a MA in Medical Biotechnology and holds a PhD in Basic and Applied Immunology. Livija conducted her research at Cancer Research UK and King’s College London before joining the biotech industry.
CFO
CFO
Julia joined Prokarium in 2021 supporting their finance operations as part-time CFO. After graduating from Loughborough University in 1997, Julia joined PriceWaterhouseCoopers and qualified as a Chartered Accountant in 2001. Julia then gained a broad range of experience with key finance positions in Industry. For the last fourteen years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made services to many companies, including IPO and fundraising support.
Julia brings 23 years’ of experience as a Finance Professional with an established record of supporting biotech companies from start up through to exit, assisting in securing and then the management of circa £200mil of Venture Capital funds. She provides strong skills in software implementation and accounting processes to aid the performance of ambitious businesses. Specialising in pharmaceutical investment funded companies.
Notable pharmaceutical clients to date include Healx Limited, AMO Pharma Limited, Ventus Medial Limited, Exvastat Limited, Amphista Therapeutics Limited, PepGen Inc, Prokarium Limited, Pheno Therapeutics Limited, Curve Therapeutics Limited, Circadian Therapeutics Limited, MiroBio Limited, Arga Medtech SA and Ivy Farm Technologies Ltd.
CMO
CMO
Josi joined Prokarium as part-time CMO in 2021. She received her training in medical oncology from the University of Marburg (Germany) and has over 25 years’ experience in pharmaceutical drug development in Europe and in North America. Josi held executive positions in international biotech companies (Ablynx NV, GPC-Biotech, U3 Pharma) and pharma organisations (Gilead Sciences, Bristol-Myers Squibb, OSI Pharmaceuticals, LEO Pharma). Josi’s portfolio experience covers more than 50 disease targets in oncology, immunology, inflammation, infectious diseases, haematology, bone disorders and dermatology in various stages of clinical validation. She also has in-depth experience in management of cross-company collaborative ventures, including partnerships with major pharma enterprises in Europe and North America and direct involvement in corporate financing initiative were part of her executive management functions.
Since 2015 Josi is an independent clinical advisor and frequently works in the function of a Part-time Chief Medical/Development Officer for biotechs. Her strategic focus is the clinically driven, stage-gate planning for biopharmaceutical companies, resulting in the successful transition of lead candidates into clinical development and product registration.
Additionally, Josi serves as medical advisor for the European Commission and is member of various medical associations such as ASCO, ESMO and SITC. She has published various articles, patents, gives invited talks and conference presentations on aspects of integrated drug development and translational research of biological medicinal products.
Chairman
Chairman
Thomas brings over 30 years of leadership and executive experience in the biopharmaceutical industry, successfully leading biotech innovation from early-stage research through commercialization. Thomas is President of Flerie Invest, a life science investment group which has financed over 20 venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. Over the course of his career, he co-founded Recipharm AB and went on to serve as its CEO, leading the company through a successful IPO in 2014. Recipharm AB remains among the top five CDMOs in the world and now includes around 30 manufacturing and development facilities in Europe, India, Israel and North America. Thomas has a MSc degree in Industrial and Management Engineering from the Linköping Institute of Technology.
Director
Director
Steve brings nearly 40 years’ experience in R&D, executive, board and advisory roles across a number of public and private healthcare organisations. He has a proven track record of success through all stages of product discovery and development leading to registration, and has provided expert advice to industry, government and non-governmental organisations on vaccines and public health issues, including biodefence. Steve is currently a Non-executive Director of the Vaccines Manufacturing & Innovation Centre (VMIC) and is also a Director of the UK Cell and Gene Therapy Catapult. At present, he is advisor to the UK Vaccine Taskforce which has been instrumental in the fight against Covid-19.
Previously, Steve served as Chief Scientific Officer and Executive Vice President of Strategic Investments for Emergent BioSolutions, a global vaccine business, and was President and CEO of its UK operation. He was also a Director of Vaccitech, a private UK vaccine specialist, and a Director of the Centre for Emergency Preparedness and Response at the UK Health Protection Agency (now Public Health England). Steve holds a PhD in microbiology and his research has led to more than 100 peer reviewed publications, as well as a number of patents.
Director
Director
Allan brings more than 40 years of experience in vaccines and biotechnology, most recently as VP Corp Dev at Sanofi Pasteur and VP BD and Strategy at Wyeth. Allan has built several smaller biotech companies as well: In 1980, Allan co-founded Damon Biotech, where he held diverse positions of increasing responsibility from Manager, Molecular Biology to VP Research and VP BD. From 1990 to 1992 he worked at Abbott Labs, as Director of Bus Dev. In 1992 he joined Repligen Corp. in the dual role of VP Business Planning for the parent company and SVP Commercial Development for its wholly owned subsidiary, Amira, Inc. Allan holds a PhD in Molecular Genetics from UC Davis.
Director
Director
Khalid is the CEO of Riyadh Valley Company (RVC) and joined the Prokarium board after investment in Prokarium in January 2018. He is also an Associate Professor in Industrial Engineering at King Saud University (KSU), has conducted consultancy work for the Saudi Ministry of Higher Education, on e.g. IP regulations, and continues to serve as the Director of the IP and Technology Licensing Programme at KSU. He has published numerous papers in the field of Industrial Engineering, is a founding-member of the Saudi Inventors Society and is a member of the Association of University Technology Managers (AUTM) amongst others. Khalid holds a B.S. in Industrial Engineering from King Saud University and a Ph.D. in Industrial Engineering from Birmingham University.
Director
Director
Sangwoo is a Managing Director and Head of Korea Investment Partners’ (KIP’s) US office based in Silicon Valley and joined the Prokarium board after investment in Prokarium in February 2018. He is responsible for the global expansion of Korea Investment Partners and actively explores cross-border investments. Sangwoo currently manages over 10 companies in his investment portfolio and participates on more than 5 boards. His portfolio companies range from biotech/healthcare companies such as Elastagen, Auris Surgical Robotics and KAHR to IT/Fintech companies such as SoFi and Le Tote. Sangwoo has started and grown two startups; Neomtel and Polidigm. Neomtel’s technology became a de-facto standard in Korea in the early 2000s and the company went IPO in 2007. Sangwoo received his B.S. and M.S. in Control and Instrumentation Engineering from Seoul National University.
Immunotherapy Advisor
Immunotherapy Advisor
Hyam joined Prokarium in 2019 as advisor in immunology, immunotherapy of cancer and research strategy, and in addition he also serves on the board of directors. Currently, he is President of Research and Development at Century Therapeutics. He was previously Executive Vice President and Chief Scientific Officer at Juno Therapeutics in Seattle, and before that, Head of Cancer Immunotherapy Experimental Medicine at Roche Pharma Research and Early Development in Switzerland. He received an MD from Johns Hopkins University School of Medicine in 1984, followed by training in internal medicine and medical oncology. He joined the Johns Hopkins faculty in 1991, rising to Professor of Oncology, Medicine and Urology in 2001 while working at the Sidney Kimmel Comprehensive Cancer Center where he served as Scientific Director of the George Santos Bone Marrow Transplant Program. Upon joining industry, he has held an adjunct professorship since 2011. His research has focused on tumour immunology, cancer vaccines, and adoptive T cell therapy. He is a Leukemia and Lymphoma Society Stohlman Scholar, a Member of theAmerican Society for Clinical Investigation, and is a founding member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Director
Director
Ted is currently CEO of NorthX Biologics, and a Partner at Flerie Invest, and has been involved in Prokarium since its inception. He also serves as a board member of several Flerie portfolio companies, including Amarna Therapeutics and Beactica Therapeutics, and heads up their UK investment operations. Earlier in his career Ted held positions in clinical research at Sahlgrenska University Hospital and in strategy consulting at Sweden’s Royal Academy of Engineering Sciences, where he coordinated the country’s national innovation strategy. Ted holds a PhD from the University of Guelph, Canada, and has been recognised as a leader in biotechnology under the Sloan Foundation funded Synthetic Biology Leadership Accelerator Program (LEAP).
Salmonella Advisor
Salmonella Advisor
David joined Prokarium in 2019 as advisor in Salmonella biology and engineering strategy. He is Professor of Molecular Microbiology in the Department of Infectious Disease at Imperial College London since 1995. David was Director of the Centre for Molecular Bacteriology and Infection (MRC CMBI),between 2012 and 2019. In 2016, he was appointed as the first Regius Professor of Infectious Disease in the UK and he is a fellow of the Royal Society, the American Academy of Microbiology, the Academy of Medical Sciences (UK), and an EMBO Member. David was co-founder of the biotech company Microscience that developed the Salmonella strain ZH9. He is best known for inventing a technique called signature-tagged mutagenesis (also termed barcoding) for identification of mutants with altered growth in mixed populations. Using STM his group has identified numerous genes of Streptococcus, Staphylococcus and Salmonella that are required for virulence.
CMC Advisor
CMC Advisor
Brigitte has been working with Prokarium since October 2021 supporting their CMC activities. She has over 10 years experience in CMC and external manufacturing, including the CMC development of an ATMP (TCR-T) and Biologicals. Brigitte worked at different biotech companies (Medigene, Micromet, Amgen) before she started to work as an independent CMC consultant. Brigitte has a Diploma in microbiology from the Technical University Munich. Her doctoral thesis focused on the immune response of an attenuated Yersinia strain as live microbial vaccine.
